31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.

      1 , ,
      Circulation
      Ovid Technologies (Wolters Kluwer Health)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the evaluation of 7E3 for the Prevention of Ischemic Complications study (EPIC), the activated coagulation (clotting) times (ACTs) were longer in heparinized patients treated with c7E3 Fab than in those treated with placebo. The present study was designed to further investigate this observation by assessing whether the in vitro addition of c7E3 Fab to blood would affect the ACT.

          Related collections

          Author and article information

          Journal
          Circulation
          Circulation
          Ovid Technologies (Wolters Kluwer Health)
          0009-7322
          0009-7322
          Feb 04 1997
          : 95
          : 3
          Affiliations
          [1 ] Department of Anesthesiology, Mount Sinai Medical Center, New York, NY 10029, USA.
          Article
          10.1161/01.cir.95.3.614
          9024148
          f434a88a-8ea2-45c4-b389-c73383c486aa
          History

          Comments

          Comment on this article